Transgene Biotek Ratios

Transgene Biotek Ltd Ratios

The Transgene Biotek Ltd Ratios page provides a complete fundamental analysis of Transgene Biotek Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Transgene Biotek Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Transgene Biotek Ltd (NSE: , BSE: 526139) is currently trading at ₹2.67, with a market capitalization of ₹175.61M. As a major player in the Health technology sector and Biotechnology industry, Transgene Biotek Ltd remains a key stock for fundamental analysis using Transgene Biotek Ltd Ratios.

Transgene Biotek Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Transgene Biotek Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Transgene Biotek Ltd Ratios.

Historically, the Transgene Biotek Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Transgene Biotek Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Transgene Biotek Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.53.

Historical P/B trend:

• 2024: 2.53
• 2023: 5.76
• 2022: 1.66
• 2021: 1.57

Transgene Biotek Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Transgene Biotek Ltd P/S ratio currently stands at 97.36, an important part of Transgene Biotek Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 97.36
• 2023: 262.57
• 2022: 342.50
• 2021: 315.51

A stable or declining Transgene Biotek Ltd P/S ratio indicates cautious market sentiment.

Transgene Biotek Ltd Price to Cash Flow Ratio (P/CF)

The Transgene Biotek Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 17.42.

Historical Transgene Biotek Ltd Price to Cash Flow Ratio:

• 2024: 17.42
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The rising Transgene Biotek Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Transgene Biotek Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Transgene Biotek Ltd EV currently stands at ₹396.18M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 396.18M
• 2023: 756.7M
• 2022: 319.76M
• 2021: 393.46M

Transgene Biotek Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Transgene Biotek Ltd EV/EBITDA ratio is currently 0, a key metric in Transgene Biotek Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Transgene Biotek Ltd EV/EBITDA indicates balanced valuation.

Transgene Biotek Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Transgene Biotek Ltd D/E ratio is currently 1.45, reflecting leverage and financial stability.

Historical D/E:

• 2024: 1.45
• 2023: 1.31
• 2022: 1.15
• 2021: 0.69

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Transgene Biotek Ltd ROE currently stands at -6.52%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -6.52
• 2023: -5.94
• 2022: -41.80
• 2021: -52.51

Declining ROE indicates pressure on profitability.

Transgene Biotek Ltd Ratios Analysis Summary

The Transgene Biotek Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Transgene Biotek Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Transgene Biotek Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.